JP Morgan Chase’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-403,077
| Closed | -$15.9M | – | 7884 |
|
|
2023
Q2 | $15.9M | Sell |
403,077
-379,019
| -48% | -$13.4M | ﹤0.01% | 1873 |
|
|
2023
Q1 | $19M | Buy |
782,096
+83,003
| +12% | +$1.82M | ﹤0.01% | 1704 |
|
|
2022
Q4 | $15M | Sell |
699,093
-110,940
| -14% | -$2.37M | ﹤0.01% | 1889 |
|
|
2022
Q3 | $14.5M | Sell |
810,033
-113,564
| -12% | -$1.49M | ﹤0.01% | 1839 |
|
|
2022
Q2 | $8.88M | Buy |
923,597
+381,732
| +70% | +$4.79M | ﹤0.01% | 2267 |
|
|
2022
Q1 | $9.12M | Buy |
541,865
+460,137
| +563% | +$6.8M | ﹤0.01% | 2466 |
|
|
2021
Q4 | $1.37M | Buy |
81,728
+35,459
| +77% | +$581K | ﹤0.01% | 4156 |
|
|
2021
Q3 | $751K | Buy |
46,269
+7,139
| +18% | +$77.7K | ﹤0.01% | 4498 |
|
|
2021
Q2 | $246K | Buy |
39,130
+8,846
| +29% | +$57.1K | ﹤0.01% | 5130 |
|
|
2021
Q1 | $187K | Sell |
30,284
-5,445
| -15% | -$33.1K | ﹤0.01% | 5180 |
|
|
2020
Q4 | $247K | Sell |
35,729
-28,500
| -44% | -$182K | ﹤0.01% | 4730 |
|
|
2020
Q3 | $347K | Sell |
64,229
-45,738
| -42% | -$218K | ﹤0.01% | 4137 |
|
|
2020
Q2 | $561K | Buy |
109,967
+92,694
| +537% | +$386K | ﹤0.01% | 3807 |
|
|
2020
Q1 | $59K | Buy |
+17,273
| New | +$101K | ﹤0.01% | 4685 |
|
|
2019
Q4 | – | Sell |
-968
| Closed | -$1K | – | 5966 |
|
|
2019
Q3 | $1K | Sell |
968
-151,352
| -99% | -$176K | ﹤0.01% | 5670 |
|
|
2019
Q2 | $184K | Buy |
152,320
+149
| +0.1% | +$204 | ﹤0.01% | 4696 |
|
|
2019
Q1 | $215K | Buy |
152,171
+56,160
| +58% | +$78.5K | ﹤0.01% | 4605 |
|
|
2018
Q4 | $115K | Buy |
96,011
+94,234
| +5,303% | +$183K | ﹤0.01% | 4794 |
|
|
2018
Q3 | $4K | Sell |
1,777
-59,716
| -97% | -$149K | ﹤0.01% | 5580 |
|
|
2018
Q2 | $168K | Buy |
+61,493
| New | +$170K | ﹤0.01% | 4637 |
|
|
2018
Q1 | – | Sell |
-201,762
| Closed | -$629K | – | 5696 |
|
|
2017
Q4 | $629K | Buy |
201,762
+169,176
| +519% | +$476K | ﹤0.01% | 3969 |
|
|
2017
Q3 | $88K | Sell |
32,586
-8,842
| -21% | -$23.9K | ﹤0.01% | 4337 |
|
|
2017
Q2 | $106K | Sell |
41,428
-98,612
| -70% | -$269K | ﹤0.01% | 4158 |
|
|
2017
Q1 | $513K | Buy |
140,040
+24,986
| +22% | +$106K | ﹤0.01% | 3697 |
|
|
2016
Q4 | $556K | Buy |
115,054
+20,487
| +22% | +$608K | ﹤0.01% | 3713 |
|
|
2016
Q3 | $4.36M | Buy |
94,567
+1,986
| +2% | +$112K | ﹤0.01% | 2351 |
|
|
2016
Q2 | $4.72M | Sell |
92,581
-2,214
| -2% | -$110K | ﹤0.01% | 2332 |
|
|
2016
Q1 | $4.01M | Sell |
94,795
-1,735
| -2% | -$88.4K | ﹤0.01% | 2336 |
|
|
2015
Q4 | $7.58M | Buy |
96,530
+35,991
| +59% | +$2.08M | ﹤0.01% | 1978 |
|
|
2015
Q3 | $2.45M | Buy |
60,539
+1,450
| +2% | +$76.8K | ﹤0.01% | 2640 |
|
|
2015
Q2 | $3.08M | Buy |
59,089
+19,764
| +50% | +$983K | ﹤0.01% | 2665 |
|
|
2015
Q1 | $1.83M | Buy |
39,325
+26,891
| +216% | +$1.4M | ﹤0.01% | 2921 |
|
|
2014
Q4 | $558K | Sell |
12,434
-2,519
| -17% | -$106K | ﹤0.01% | 3619 |
|
|
2014
Q3 | $582K | Sell |
14,953
-466
| -3% | -$18.3K | ﹤0.01% | 3591 |
|
|
2014
Q2 | $652K | Sell |
15,419
-4,786
| -24% | -$176K | ﹤0.01% | 3027 |
|
|
2014
Q1 | $720K | Sell |
20,205
-63,091
| -76% | -$2.13M | ﹤0.01% | 2998 |
|
|
2013
Q4 | $2.69M | Buy |
+83,296
| New | +$2.47M | ﹤0.01% | 2564 |
|
JP Morgan Chase's ISEE Position: Q3 2023 in Review
JP Morgan Chase sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 403,077 shares — an estimated $15.9M sold.
JP Morgan Chase first reported a position in ISEE in Q4 2013 and held it in 37 quarters. The position peaked at $19M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- JP Morgan Chase reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- JP Morgan Chase sold 403,077 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $15.9M.
- JP Morgan Chase first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 37 quarters.
- JP Morgan Chase's IVERIC bio, Inc. Common Stock position peaked at $19M in Q1 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.